Argitalpenak (32) Carolina María Perdomo Zelaya argitalpenak

2024

  1. Cardiometabolic risk stratification using a novel obesity phenotyping system based on body adiposity and waist circumference

    European Journal of Internal Medicine, Vol. 124, pp. 54-60

  2. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  3. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  4. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry

    High Blood Pressure and Cardiovascular Prevention, Vol. 31, Núm. 1, pp. 43-53

  5. Revisiting the beyond BMI paradigm in excess weight diagnosis and management: A call to action

    European Journal of Clinical Investigation, Vol. 54, Núm. 7

2023

  1. Antidiabetic Drugs That Reduce Weight and Are Cardioprotective

    Handbook of Obesity - Volume 2: Clinical Applications, Fifth Edition (CRC Press), pp. 318-332

  2. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  3. Contemporary medical, device, and surgical therapies for obesity in adults

    The Lancet, Vol. 401, Núm. 10382, pp. 1116-1130

  4. Effect of Obesity on Clinical Characteristics of Primary Aldosteronism Patients at Diagnosis and Postsurgical Response

    The Journal of clinical endocrinology and metabolism, Vol. 109, Núm. 1, pp. e379-e388

  5. Evaluation of Dietary and Alcohol Drinking Patterns in Patients with Excess Body Weight in a Spanish Cohort: Impact on Cardiometabolic Risk Factors

    Nutrients, Vol. 15, Núm. 22

  6. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

    Journal of Endocrinological Investigation, Vol. 46, Núm. 11, pp. 2343-2352

  7. Towards an adiposity-related disease framework for the diagnosis and management of obesities

    Reviews in Endocrine and Metabolic Disorders, Vol. 24, Núm. 5, pp. 795-807

2022

  1. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register)

    Endocrine, Vol. 78, Núm. 2, pp. 363-372

  2. Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease

    Frontiers in Medicine, Vol. 9

  3. Differences in the presentation and evolution of primary aldosteronism in elderly (≥65 years) and young patients (<65 years)

    Endocrine Connections, Vol. 11, Núm. 6

  4. Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry

    Endocrine, Vol. 76, Núm. 3, pp. 687-696

  5. Predictive model of hypertension resolution after adrenalectomy in primary aldosteronism: the SPAIN-ALDO score

    Journal of Hypertension, Vol. 40, Núm. 12, pp. 2486-2493

  6. Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD

    Scientific Reports, Vol. 12, Núm. 1

  7. ‘Obesities’: Position statement on a complex disease entity with multifaceted drivers

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

2021

  1. Diabetic kidney disease, cardiovascular disease and non-alcoholic fatty liver disease: A new triumvirate?

    Journal of Clinical Medicine, Vol. 10, Núm. 9